Double gene overexpression of ZNF746 and cellular prion protein in rat adipose-derived mesenchymal stromal cell therapy protects the liver against ischemia‒reperfusion injury.
Ko SF., Huang CR., Chiang JY., Chen YL., Yip HK.
Animal Study with a reported sample of 50, published in Cell Transplant (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Cell Transplant (2025)
- Country
- United States
- Reported sample size
- 50
- Source database
- PubMed
- PMID
- 41104900
- PMCID
- PMC12541172
- DOI
- 10.1177/09636897251381882
- Citations
- 1
Abstract (original English)
This study presents an examination of whether the double overexpression of ZNF746 and cellular prion protein (PrP C ) genes in rat adipose-derived mesenchymal stromal cells (ADMSCs) (ie, MSC DGe-OVE ) offered enhanced protection to the livers of rats against ischemia‒reperfusion (IR) injury. The in vitro results revealed that compared with those of rat ADMSCs, cell activities (viability/proliferation/growth/cell cycle process) were significantly upregulated by the overexpression of either gene in rat ADMSCs and were further significantly increased by MSC DGe-OVE , whereas the expression of biomarkers of oxidative stress/ROS/apoptosis/fibrosis/autophagy decreased with increasing cell viability among the groups (all P < 0.001). Male adult SD rats (n = 50) were equally categorized into groups 1 (sham-operated-control), 2 (IR), 3 (IR-MSC OVE-PrPC ), 4 (IR-MSC OVE- ZNF746 ), and 5 (IR-MSC DGe-OVE ), and livers were harvested by day 3. By day 3, the number of circulatory inflammatory/immune cells, protein expression of oxidative stress/apoptotic/fibrotic/mitochondrial damage/autophagic biomarkers, and cellular levels of DNA damage/fibrosis/inflammation in the liver parenchyma were lowest in group 1, highest in group 2 and significantly lower in groups 3/4 than in group 5 (all P < 0.0001). Liver fibrosis detected by ultrasound and the liver injury score displayed identical patterns of
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.